668476-66-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 668476-53-7 8-chloro-2,3,4,5-tetrahydro-3-methyl-5(R)-phenyl-1H-3-benzazepin-6,7-diamine 
• 668476-51-5 N-[8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5(R)-phenyl-1H-3-benzazepin-7-yl]-2-hydroxyacetamide 
• 668476-50-4 2-[[8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5(R)-phenyl-1H-3-benzazepin-7-yl]oxy]acetamide 
• 668476-52-6 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5(R)-phenyl-1H-3-benzazepin-7-amine 
• 668476-49-1 8-chloro-2,3,4,5-tetrahydro-3-methyl-6-nitro-5(R)-phenyl-1H-3-benzazepin-7-ol 
• 73445-63-3 SCH 23390 

Relevant academic research and scientific papers

Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: Design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists

Benzazepines 1 and 2 (SCH 23390 and SCH 39166, respectively) are two classical benzazepine D1/D5 antagonists, with K i values 1.4 and 1.2 nM, respectively. Compound 2 has been in human clinical trials for a variety of dise

SELECTIVE D1/D5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS

The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonist